Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics President, R&D & CMO Harold Bernstein executed an option exercise and share sale in a pre-planned transaction. He exercised stock options to acquire 14,609 shares of Common Stock at an exercise price of $10.42 per share and then sold 14,609 shares in open-market trades on the same date.
The sales occurred at weighted average prices of $29.8650 and $30.3369 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. Following these transactions, he reported holding 0 shares of Common Stock directly and 192,945 stock options (right to buy) outstanding.
Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported indirect open-market sales of common stock totaling 34,501 shares on July 1, 2026, executed by family trusts.
The Coloma Family Trust sold 1,597 shares at a weighted average of $30.4359 per share and 30,311 shares at a weighted average of $29.9535 per share. The Coloma 2021 Irrevocable Trust sold 2,593 shares at a weighted average of $29.9754 per share. According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were scheduled in advance rather than timed discretionarily.
MAZE submitted a Form 144 notice indicating a proposed sale of 46,892 common shares scheduled on 07/01/2026. The filing lists an exercise of stock options as the transfer method and shows cash proceeds treatment. The record includes two 10b5-1 sales by Harold Bernstein totaling 29,853 shares on 05/14/2026 and 06/01/2026, with reported proceeds of $393,354.00 and $381,113.13 respectively.
Maze Therapeutics CSBO Atul Dandekar executed an option exercise and share sale. On June 29, he exercised 7,500 stock options at $10.42 per share and sold 7,500 shares of common stock at $28.02 per share in an open-market transaction.
These trades were made under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he holds 26,250 shares of common stock directly, including 1,442 shares acquired through the company’s Employee Stock Purchase Plan.
MAZE reported multiple resale transactions by related trusts under Form 144, showing sales of Common stock in May–June 2026. The entries list specific dispositions by the Coloma Family Trust and the Coloma 2021 Irrevocable Trust, with individual trades (shares and proceeds) dated between 05/15/2026 and 06/23/2026.
Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported indirect open-market sales totaling 27,858 shares of common stock. The Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Coloma and his spouse serve as co-trustees, executed these trades at weighted average prices near $26 per share. The filing notes the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were pre-arranged rather than discretionary market-timed sales.
Maze Therapeutics, Inc. director Daniel K. Spiegelman received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.
Maze Therapeutics, Inc. director Richard H. Scheller received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036.
The option award vests and becomes fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, as long as Scheller continues to serve the company through that vesting date. This is a compensation-related grant rather than an open‑market transaction.
Maze Therapeutics director Jonathan E. Lim received a grant of 18,000 stock options for common stock. The options have an exercise price of $23.58 per share and bring his reported option holdings to 18,000.
The award vests and becomes fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, if he continues serving the company through that date. This is a compensation-related grant rather than an open-market purchase or sale.
Maze Therapeutics director Herve Hoppenot received a grant of stock options to buy 18,000 shares of Common Stock at an exercise price of $23.58 per share. The options were granted on June 8, 2026 and will vest fully on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, contingent on his continued service. The options expire on June 7, 2036 and are held directly, representing equity-based, non-cash compensation rather than an open-market transaction.